Alumis Inc. Common Stock (ALMS) - Stock Analysis
Last updated: Apr 11, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Severe cash burn ⢠Extremely overvalued As of 2025â12â31 ALMS has strong liquidity and low debt but is suffering severe cash burn, deep operating losses and negative returns while trading at extreme valuation multiples.
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Near support ⢠Elevated volatility Support Level: $21.94 (secondary $20.21) Resistance Level: $25â$26 (peak $26.31) ALMS is in a short-term downtrendâprice declined ~8% over the last month, trading below the last-month 21-day SMA (~$23.90) and nearer the lower half of a volatile $20.21â$26.31 range, with immediate support near $21.94 and clear resistance around $25â$26 that must be cleared to reverse momentum.
Sentiment & News
Key News Insights: ⢠Strong Phaseâ3 efficacy ⢠Favorable safety ⢠H2 2026 NDA Alumis' envudeucitinib posted strong Phase 3 psoriasis results with high skin-clearance rates and favorable safety, prompting investor upgrades, AAD late-breaking presentations, and a planned H2 2026 NDA submission.
AI Summary
ALMS has shifted from an early R&D binary to a commercializationâdriven investment where Phase 3 success materially derisks the story but the critical nearâterm determinant is whether management can file a highâquality NDA, disclose safety/adverseâevent tables that demonstrate differentiation, and secure nonâdilutive financing or a strong partner to fund a capitalâefficient launchâfailure on any of those (NDA delay, adverse safety detail, or dilutive financing) would rapidly reprice downside.
Description
Alumis Inc. is a clinical-stage biopharmaceutical company developing allosteric TYK2 inhibitors to treat autoimmune conditions. Its lead program, ESK-001, is in clinical development for dermatologic, systemic and ocular autoimmune disorders, while A-005 is a CNS-penetrant candidate intended for neuroinflammatory and neurodegenerative indications. The company was incorporated in 2021, renamed from Esker Therapeutics in January 2022, and is based in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 29 | Feb 5 | ALMS | Alumis Inc. Common Stock | Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst. | Closed | -1.9% |
| Jan 7 | Jan 14 | ALMS | Alumis Inc. Common Stock | Selected due to recent Phase 3 clinical trial success on 2026-01-07 driving strong near-term momentum and technical breakout; event-driven upside expected from FDA submission and regulatory catalysts. | Closed | +35.8% |